Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.

@article{Andr1999MulticenterPI,
  title={Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.},
  author={Thierry Andr{\'e} and M A Bensmaine and Christophe Louvet and {\'E}ric François and Virginie Lucas and Françoise Desseigne and Karine Beerblock and Olivier Bouch{\'e} and Elisabeth Carola and Yacine Merrouche and François Morvan and G Dupont-Andr{\'e} and Aimery de Gramont},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1999},
  volume={17 11},
  pages={3560-8}
}
PURPOSE To evaluate the objective tumor response rates and toxicities of leucovorin (LV) plus fluorouracil (5-FU) cancer regimen combined with oxaliplatin (85 mg/m(2)) every 2 weeks on metastatic colorectal cancer patients with documented proof of progression while on bimonthly LV and 5-FU alone. PATIENTS AND METHODS One hundred patients were enrolled onto this study and 97 received the study drugs between October 1995 and December 1996. Eighty-nine patients were eligible for per-protocol… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 95 extracted citations

Similar Papers

Loading similar papers…